UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 11, 2011
OPEXA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Texas | 001-33004 | 76-0333165 | ||
(State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification |
2635 Technology Forest Blvd., The Woodlands, Texas | 77381 |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code: (281) 272-9331 |
| N/A |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 | Other Events |
On November 11, 2011, Opexa Therapeutics, Inc. (the “Company”) issued a press release announcing that Neil K. Warma, the Company’s President and Chief Executive Officer, will deliver a corporate presentation at the Lazard Capital Markets 8th Annual Healthcare Conference. The Company’s presentation will take place at 10:30 a.m. (ET) on Wednesday, November 16, 2011, at The Pierre Hotel in New York City. The presentation will include an overview of the Company’s ongoing clinical development program for Tovaxin®, the Company’s lead therapy for multiple sclerosis. The presentation will be webcasted and the link to access the audio webcast and the presentation materials will be available at the Investor Relations page of the Company’s website at www.opexatherapeutics.com.
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
Exhibit No. | Description |
| 99.1 | Press release issued November 11, 2011 by Opexa Therapeutics, Inc. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: | November 11, 2011 | OPEXA THERAPEUTICS, INC. | |
|
|
| |
By: | /s/ Neil K. Warma | ||
Neil K. Warma | |||
President & Chief Executive Officer | |||
Exhibit Index
Exhibit No. | Description |
99.1 | Press release issued November 11, 2011 by Opexa Therapeutics, Inc. |